EGFR and non-small cell lung carcinoma: The third-generation EGFR-TKI, osimertinib, was approved for the treatment of advanced NSCLC with EGFR-sensitive mutations and acquired T790M mutations, as well as for the postoperative adjuvant treatment of NSCLC driven by positive genes (Mok T. S. et al., 2017; Ramalingam et al., 2020; Tsuboi et al., 2023).